Screening for prostate cancer remains controversial.

  title={Screening for prostate cancer remains controversial.},
  author={David E. Neal and Jenny L Donovan and Richard M. Martin and Freddie Hamdy},
  volume={374 9700},
The eff ectiveness of prostate-cancer screening with prostate-specifi c antigen (PSA) for mortality reduction and quality-of-life improvement remains uncertain after the recent publication of two large trials—the European randomised study of screening for prostate cancer (ERSPC) and the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. ERSPC studied 162 000 men randomised to receive PSA testing every 4 years or no screening. With a median follow-up of 9 years, prostate… CONTINUE READING

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 30 extracted citations

[PSA testing, biopsy and cancer and benign prostate hyperplasia in France].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie • 2014
View 3 Excerpts


Publications referenced by this paper.
Showing 1-10 of 18 references

Similar Papers

Loading similar papers…